Indian drug manufacturers benefit from Big Pharma interest beyond China thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.
Drugmakers are reducing their reliance on Chinese contractors and turning to manufacturers in India for clinical trials and early-stage manufacturing, as tensions with China and concerns over supply chain exposure increase.
Drugmakers
are seeking to limit their reliance on Chinese contractors who
produce drugs used in clinical trials and early-stage
manufacturing, a move that is benefiting rivals in India,
according to.
Drugmakers are seeking to limit their reliance on Chinese contractors who produce drugs used in clinical trials and early-stage manufacturing, a move that is benefiting rivals in India, according to interviews with 10 industry executives and experts. China has for nearly 20 years been the preferred location for a range of pharmaceutical research and manufacturing services due to the low cost and speed offered by contract drugmakers there. That is leading some biotech companies to consider using manufacturers in India to produce active pharmaceutical ingredient (API) for clinical trials or other outsourced work.